Fraunhofer USA Center for Molecular Biotechnology Confirms Interim Results for its Plant-Produced H1N1 Influenza Vaccine  
3/21/2012 6:09:48 AM

NEWARK, Del.--(BUSINESS WIRE)--Fraunhofer USA Center for Molecular Biotechnology (CMB), a not-for-profit, Delaware-based organization focused on developing a proprietary plant-based protein production platform and its applications in vaccine and therapeutic fields, today confirms the interim results from the first human trial of plant-produced H1N1 influenza vaccine (HAC1) that began 13 September, 2010 and ended 5 May, 2011. This Phase 1, single-blind, placebo-controlled, dose-escalation study was conducted to assess the safety and reactogenicity and immunogenicity of CMB’s HAC1. The trial was supported by funding from the Defense Advanced Research Projects Agency (DARPA) and was conducted at the Walter Reed Army Institute of Research Clinical Trials Center (WRAIR-CTC). Safety and reactogenicity assessments were completed at WRAIR-CTC and immunogenicity evaluation was performed by the Influenza Division of the Centers for Disease Control and Prevention.